Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo versus sunitinib.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but ...

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...